2022 World Conference on Lung Cancer (ePosters)-EP08.02-101. Real-world Data from KRAS-mutant Advanced NSCLC: the ATLAS Multicenter Cohort Study

Pdf Summary

The ATLAS multicenter cohort study analyzed real-world clinical data from patients with advanced non-small cell lung cancer (NSCLC) with KRAS mutations who received standard first-line therapies in Italy. KRAS mutations are the most common oncogenic driver in non-squamous NSCLC. The study found that the prevalence of KRAS mutation subtypes and survival outcomes were consistent with previous literature, highlighting the high heterogeneity of the KRAS-mutant NSCLC population and the need for personalized treatment strategies. The median overall survival (mOS) for the entire cohort was 12.9 months. The mOS for patients with different KRAS mutation subtypes (p.G12C, p.G12A, p.G12D, p.G12V) ranged from 7.13 to 14.98 months, with no significant differences between subtypes. The study also provided information on patient characteristics, treatments, safety, and PD-L1 expression levels. The majority of patients were males, current or former smokers, and had adenocarcinoma. The most common first-line treatment was chemo-immunotherapy. Around 7.3% of patients were enrolled in clinical trials. Grade 3 toxicities were reported in 26% of patients, with hematological and gastrointestinal toxicities being the most common. 8.9% of patients discontinued treatment due to toxicity. 39% of patients received second-line therapy, and 18 patients received third-line therapy. The study findings confirm the real-world clinical features and survival outcomes of patients with KRAS-mutant advanced NSCLC in Italy and emphasize the need for novel personalized treatment strategies in this population.

Asset Subtitle

Maristella Bungaro

Meta Tag

Speaker Maristella Bungaro

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ATLAS multicenter cohort study

advanced non-small cell lung cancer

NSCLC

KRAS mutations

first-line therapies

Italy

oncogenic driver

personalized treatment strategies

median overall survival

patient characteristics